Liu, Pei Y <br/><br/>
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.  [electronic resource] 

 -  Oncotarget  Nov 2016 
 - 79217-79232 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.12640  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Azepines--administration & dosage<br/>Cell Cycle Proteins<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Drug Synergism<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Mice<br/>NF-E2-Related Factor 2--metabolism<br/>Naphthoquinones--administration & dosage<br/>Neuroblastoma--drug therapy<br/>Nuclear Proteins--metabolism<br/>Protein Domains--drug effects<br/>RNA-Binding Proteins--metabolism<br/>Small Molecule Libraries--administration & dosage<br/>Transcription Factors--metabolism<br/>Triazoles--administration & dosage<br/>Tubulin Modulators--administration & dosage<br/>Vincristine--administration & dosage<br/>Xenograft Model Antitumor Assays